America Targets Patented Medicines With Steep Tariffs, India’s Pharma Industry Braces For Mixed Impact

The US government has announced tariffs of up to 100% on patented pharmaceutical imports, citing national security and supply chain risks. While the measure is designed to push global drugmakers to shift production to the US, India’s pharmaceutical industry faces a nuanced impact due to its dominance in generics.

Policy Background

The tariffs follow a Section 232 investigation into pharmaceutical supply chains, with the US administration arguing that over-reliance on foreign patented drugs poses risks. The new regime applies primarily to patented medicines manufactured in countries without trade agreements with the US.

Impact On Indian Pharma

India, a global leader in generic drug exports, is expected to see limited direct disruption. Generic medicines, which account for nearly 90% of US prescriptions, are exempt from the tariff. However, Indian firms producing branded generics or collaborating on patented drugs may face pricing pressures and reduced competitiveness.

Market Outlook

Analysts suggest the move could benefit India’s generics sector by reinforcing its cost advantage, but warn of potential risks if the US expands tariffs to include branded generics. For patients, the tariffs may drive up costs of patented drugs in the US, while Indian companies could explore opportunities to expand generic supply.

Key Highlights

* US imposes 100% tariff on patented pharmaceutical imports

* Tariffs exclude generic drugs, India’s strongest export segment

* Branded generics may face classification risks and pricing challenges

* Policy aims to push global drugmakers to build US manufacturing facilities

* India’s $30 billion pharma export industry remains cautiously optimistic

Sources: Fortune India, Republic World, News24, Times of India, Hindustan Times